BRPI0918971A2 - tienopirimidinas para composições farmacêuticas - Google Patents

tienopirimidinas para composições farmacêuticas

Info

Publication number
BRPI0918971A2
BRPI0918971A2 BRPI0918971A BRPI0918971A BRPI0918971A2 BR PI0918971 A2 BRPI0918971 A2 BR PI0918971A2 BR PI0918971 A BRPI0918971 A BR PI0918971A BR PI0918971 A BRPI0918971 A BR PI0918971A BR PI0918971 A2 BRPI0918971 A2 BR PI0918971A2
Authority
BR
Brazil
Prior art keywords
thienopyrimidines
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
BRPI0918971A
Other languages
English (en)
Inventor
Ian Linney
John Danilewicz
Kay Schreiter
Martin Scheneider
Matthias Austen
Phillip Black
Wesley Blackaby
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40266066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0918971(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0918971A2 publication Critical patent/BRPI0918971A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0918971A 2008-08-26 2009-08-24 tienopirimidinas para composições farmacêuticas BRPI0918971A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08015049 2008-08-26
PCT/EP2009/060876 WO2010023181A1 (en) 2008-08-26 2009-08-24 Thienopyrimidines for pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BRPI0918971A2 true BRPI0918971A2 (pt) 2015-12-01

Family

ID=40266066

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918971A BRPI0918971A2 (pt) 2008-08-26 2009-08-24 tienopirimidinas para composições farmacêuticas

Country Status (18)

Country Link
US (1) US8486953B2 (pt)
EP (1) EP2331551B1 (pt)
JP (1) JP5675614B2 (pt)
KR (1) KR20110045019A (pt)
CN (1) CN102186857A (pt)
AR (1) AR073209A1 (pt)
AU (1) AU2009286734A1 (pt)
BR (1) BRPI0918971A2 (pt)
CA (1) CA2735361A1 (pt)
CL (1) CL2011000409A1 (pt)
ES (1) ES2593495T3 (pt)
IL (1) IL211008A0 (pt)
MX (1) MX2011001938A (pt)
NZ (1) NZ591113A (pt)
RU (1) RU2011110908A (pt)
TW (1) TW201014864A (pt)
UY (1) UY32072A (pt)
WO (1) WO2010023181A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655799A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
UY32072A (es) 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
MX2012009851A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
US20130065914A1 (en) * 2010-02-26 2013-03-14 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
JP5575274B2 (ja) * 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
CN103841967A (zh) * 2011-07-29 2014-06-04 约兰·K·汉松 用于预防和治疗高脂血症及其心血管并发症的3-羟基氨基苯甲酸（3-haa）疗法
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
EP2802590B1 (en) * 2012-01-10 2017-03-01 F. Hoffmann-La Roche AG Thienopyrimidine compounds
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
HK1206723A1 (en) 2012-05-21 2016-01-15 Bayer Pharma Aktiengesellschaft Thienopyrimidines
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2917185B1 (en) * 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
JP2016514087A (ja) 2013-02-01 2016-05-19 バイエル・ファルマ・アクティエンゲゼルシャフト 置換チエノピリミジンおよびその薬学的使用
CA2899662A1 (en) 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
WO2014135480A1 (en) 2013-03-06 2014-09-12 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
US10167296B2 (en) * 2014-05-07 2019-01-01 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
JP2017519737A (ja) * 2014-05-26 2017-07-20 バイエル・ファルマ・アクティエンゲゼルシャフト 置換テトラヒドロピリドチエノピリミジン
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
EP3285809B1 (en) * 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
WO2017117052A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
EP3548035A4 (en) * 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
CA3053493A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
PT3802517T (pt) 2018-06-07 2023-03-20 Idorsia Pharmaceuticals Ltd Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH408945A (de) 1956-02-10 1966-03-15 Ciba Geigy Verfahren zur Herstellung von heterocyclischen Verbindungen
DD248593A1 (de) 1985-01-11 1987-08-12 Univ Halle Wittenberg Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EP1028964A1 (en) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US20030162795A1 (en) 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
MXPA03009925A (es) 2001-04-30 2004-06-30 Bayer Pharmaceuticals Corp Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas.
JP4518378B2 (ja) 2001-10-29 2010-08-04 ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング エネルギー恒常性および細胞小器官代謝の調節に関与するＭｎｋキナーゼ相同性タンパク質
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
ES2304252T3 (es) 2003-05-28 2008-10-01 Universita Degli Studi Di Siena Derivados sustituidos en posicion 4 de pirazolo(3,4-d)pirimidina y utilizaciones de los mismos.
CA2528602A1 (en) 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
ES2280040T3 (es) 2003-07-24 2007-09-01 Bayer Pharmaceuticals Corporation Compuestos de tetrahidrobenzotienopirimidinamina sustituidos utiles para tratar trastornos hiperproliferativos.
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
WO2005067908A2 (en) 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
JP5328342B2 (ja) 2005-03-08 2013-10-30 ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｎｋ−１タンパク質およびＭｎｋ−２タンパク質の結晶学的構造
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
KR101378716B1 (ko) 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
CA2655799A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
US20070099877A1 (en) 2005-11-02 2007-05-03 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007056214A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
WO2007059905A2 (en) 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
US20080108611A1 (en) * 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
US20080039450A1 (en) 2006-06-22 2008-02-14 Jensen Annika J Compounds
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2009065596A2 (en) 2007-11-22 2009-05-28 Develogen Aktiengesellschaft Use of mnk inhibitors for the treatment of alzheimer's disease
CN104135343B (zh) 2008-01-25 2018-02-06 华为技术有限公司 基站设备和方法
US20100015708A1 (en) 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
UY32072A (es) 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
US20130065914A1 (en) 2010-02-26 2013-03-14 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
JP5575274B2 (ja) 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
MX2012009851A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
ES2583015T3 (es) 2011-09-07 2016-09-16 Nordex Energy Gmbh Procedimiento para la fabricación de un componente de pala de rotor de instalación de energía eólica con un larguero principal prefabricado

Also Published As

Publication number Publication date
JP5675614B2 (ja) 2015-02-25
WO2010023181A1 (en) 2010-03-04
RU2011110908A (ru) 2012-10-10
JP2012500825A (ja) 2012-01-12
CN102186857A (zh) 2011-09-14
US8486953B2 (en) 2013-07-16
TW201014864A (en) 2010-04-16
UY32072A (es) 2010-03-26
KR20110045019A (ko) 2011-05-03
AR073209A1 (es) 2010-10-20
EP2331551A1 (en) 2011-06-15
AU2009286734A1 (en) 2010-03-04
IL211008A0 (en) 2011-04-28
EP2331551B1 (en) 2016-06-29
CA2735361A1 (en) 2010-03-04
ES2593495T3 (es) 2016-12-09
MX2011001938A (es) 2011-03-29
US20120128686A1 (en) 2012-05-24
NZ591113A (en) 2012-07-27
CL2011000409A1 (es) 2011-07-29

Similar Documents

Publication Publication Date Title
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
LTPA2018005I1 (lt) Farmacinė kompozicija
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
BRPI1012539A2 (pt) composições farmacêuticas
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
SMT201700008B (it) Composizione farmaceutica
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
RU2493831C3 (ru) Фармацевтические композиции
IT1394860B1 (it) Composti farmaceutici
BRPI1015939A2 (pt) composição farmacêutica
DK3246018T3 (da) Farmaceutisk sammensætning
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
DK2120884T3 (da) Farmaceutisk sammensætning
IT1394400B1 (it) Composizioni farmaceutiche
DK2285413T3 (da) Farmaceutisk sammensætning
EE201300005A (et) Ravimkoostis
BR112012004080A2 (pt) composições farmacêuticas para tratar ibd
BRPI0921313A2 (pt) composição farmaucêutica
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI0910545A2 (pt) processo contínuo para fazer composições farmacêuticas
PT2209464E (pt) Composição farmacêutica antimalárica
BRPI0820198A2 (pt) composições farmacêuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.